{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:13:43Z","timestamp":1788236023955,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic and Interventional Imaging"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.diii.2026.02.009","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T17:54:19Z","timestamp":1772474059000},"page":"306-315","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Total tumor volume and growth rate at 3 months on MRI outperform baseline imaging and circulating tumor DNA for predicting survival of patients with metastatic uveal melanoma receiving tebentafusp"],"prefix":"10.1016","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8440-7785","authenticated-orcid":false,"given":"Toulsie","family":"Ramtohul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier-Louis","family":"Jasawant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Sandoval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9ah","family":"Mailly-Giacchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00eblle","family":"Pierron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Cassoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2648-0367","authenticated-orcid":false,"given":"Pascale","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8100-2272","authenticated-orcid":false,"given":"Marc-Henri","family":"Stern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shufang","family":"Renault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2154-6376","authenticated-orcid":false,"given":"Aurore","family":"Rampanou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Piperno-Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Servois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diii.2026.02.009_bib0001","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/CMR.0000000000000575","article-title":"Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis","volume":"29","author":"Rantala","year":"2019","journal-title":"Melanoma Res"},{"key":"10.1016\/j.diii.2026.02.009_bib0002","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diii.2026.02.009_bib0003","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1056\/NEJMoa2304753","article-title":"Three-year overall survival with tebentafusp in metastatic uveal melanoma","volume":"389","author":"Hassel","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diii.2026.02.009_bib0004","doi-asserted-by":"crossref","first-page":"S1210","DOI":"10.1016\/j.annonc.2021.08.1702","article-title":"Early reduction in ctDNA, regardless of best RECIST response, is associated with overall survival on tebentafusp in previously treated metastatic uveal melanoma patients","volume":"32","author":"Shoushtari","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.diii.2026.02.009_bib0005","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1038\/s41591-022-02015-7","article-title":"Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial","volume":"28","author":"Carvajal","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.diii.2026.02.009_bib0006","doi-asserted-by":"crossref","first-page":"8851","DOI":"10.1038\/s41467-024-53145-0","article-title":"Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafusp","volume":"15","author":"Rodrigues","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.diii.2026.02.009_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115687","article-title":"Uveal melanoma UK national guidelines: 2023 update","volume":"228","author":"Carter","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.diii.2026.02.009_bib0008","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-012799","article-title":"STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration","volume":"6","author":"Cohen","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.diii.2026.02.009_bib0009","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1158\/1078-0432.CCR-13-2098","article-title":"Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials","volume":"20","author":"Fert\u00e9","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.diii.2026.02.009_bib0010","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.diii.2024.11.003","article-title":"An introductory guide to statistics for the radiologist","volume":"106","author":"O\u2019Shaughnessy","year":"2025","journal-title":"Diagn Interv Imaging"},{"key":"10.1016\/j.diii.2026.02.009_bib0011","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1200\/JCO.21.01805","article-title":"Phase I study of safety, tolerability, and efficacy of tebentafusp using a step-up dosing regimen and expansion in patients with metastatic uveal melanoma","volume":"40","author":"Carvajal","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.diii.2026.02.009_bib0012","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-20-1247","article-title":"Tebentafusp, a TCR\/anti-CD3 bispecific fusion protein targeting gp100, potently activated antitumor immune responses in patients with metastatic melanoma","volume":"26","author":"Middleton","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.diii.2026.02.009_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115634","article-title":"Real-life data on tebentafusp in metastatic uveal melanoma patients from four EURACAN expert centres","volume":"227","author":"van der Kooij","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.diii.2026.02.009_bib0014","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/ced\/llae427","article-title":"Early poliosis- and vitiligo-like depigmentation as an indicator of treatment response in patients with uveal melanoma under tebentafusp therapy","volume":"50","author":"Helf","year":"2025","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.diii.2026.02.009_bib0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120181","article-title":"Development and external validation of a prognostic nomogram for metastatic uveal melanoma","volume":"10","author":"Valpione","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.diii.2026.02.009_bib0016","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ajo.2016.06.002","article-title":"Validation of a prognostic staging for metastatic uveal melanoma: a collaborative study of the European Ophthalmic Oncology Group","volume":"168","author":"Kivel\u00e4","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.diii.2026.02.009_bib0017","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3390\/cancers11060863","article-title":"Development of a prognostic nomogram for liver metastasis of uveal melanoma patients selected by liver MRI","volume":"11","author":"Mariani","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.diii.2026.02.009_bib0018","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.232674","article-title":"Liquid biopsy versus CT: comparison of tumor burden quantification in 1065 patients with metastases","volume":"313","author":"Dawi","year":"2024","journal-title":"Radiology"},{"key":"10.1016\/j.diii.2026.02.009_bib0019","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.diii.2025.06.002","article-title":"Baseline CT-derived tumor burden and liquid biopsy as biomarkers to predict survival in patients with metastatic solid cancer","volume":"106","author":"Jardali","year":"2025","journal-title":"Diagn Interv Imaging"},{"key":"10.1016\/j.diii.2026.02.009_bib0020","doi-asserted-by":"crossref","DOI":"10.1111\/pcmr.70047","article-title":"Prognostic and predictive value of ctDNA for metastatic uveal melanoma: a systematic review and meta-analysis","volume":"38","author":"Noronha","year":"2025","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.diii.2026.02.009_bib0021","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diii.2026.02.009_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2025.112038","article-title":"RECIST progression: patterns among target, non-target, non-measurable and new lesions progression","volume":"186","author":"Tareco Bucho","year":"2025","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.diii.2026.02.009_bib0023","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231160140","article-title":"Tebentafusp: a first-in-class treatment for metastatic uveal melanoma","volume":"15","author":"Howlett","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.diii.2026.02.009_bib0024","doi-asserted-by":"crossref","first-page":"TPS9613","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS9613","article-title":"PLUME: a single-arm phase II trial evaluating the combination of pembrolizumab and lenvatinib in metastatic uveal melanoma patients previously treated or not with tebentafusp","volume":"41","author":"Rodrigues","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.diii.2026.02.009_bib0025","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1200\/JCO.22.01705","article-title":"Isolated hepatic perfusion with melphalan for patients with isolated uveal melanoma liver metastases: the SCANDIUM trial","volume":"41","author":"Olofsson Bagge","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.diii.2026.02.009_bib0026","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2022.40.16_suppl.3068","article-title":"Lesion-specific radiomics analysis shows promising results for early-stage efficacy assessment of IOA-244 in uveal melanoma","volume":"40","author":"Gueuning","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.diii.2026.02.009_bib0027","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.diii.2025.07.005","article-title":"Volumetric tumor burden and liquid biopsy metrics as emerging biomarkers in solid cancer","volume":"106","author":"Rowe","year":"2025","journal-title":"Diagn Interv Imaging"},{"key":"10.1016\/j.diii.2026.02.009_bib0028","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.241613","article-title":"TotalSegmentator MRI: robust sequence-independent segmentation of multiple anatomic structures in MRI","volume":"314","author":"Akinci D\u2019Antonoli","year":"2025","journal-title":"Radiology"}],"container-title":["Diagnostic and Interventional Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211568426000483?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211568426000483?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T03:17:32Z","timestamp":1788232652000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211568426000483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2211568426000483"],"URL":"https:\/\/doi.org\/10.1016\/j.diii.2026.02.009","relation":{},"ISSN":["2211-5684"],"issn-type":[{"value":"2211-5684","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Total tumor volume and growth rate at 3 months on MRI outperform baseline imaging and circulating tumor DNA for predicting survival of patients with metastatic uveal melanoma receiving tebentafusp","name":"articletitle","label":"Article Title"},{"value":"Diagnostic and Interventional Imaging","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diii.2026.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Soci\u00e9t\u00e9 fran\u00e7aise de radiologie. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}